5Lapum JL. Patency of arterial catheters with heparinized solutions versus non-heparinized solutions: a review of the literature[J]. Can J Cardiovasc Nurs,2006,16(2) : 64-70.
2Kehon JG. The pathophysiology of heparin induced thrombocytopenia : biological basis for treatment. Chest,2005,127 : 9S-20S.
3Baldwin ZK, Spitzer AL, Ng VL, et al. Contemporary standards for the diagnosis and treatment of heparin induced thrombocytopenia (HIT). Surgery,2008,143:305-312.
4Warkentin TE. Think of HIT. Hematology Am Soc I-Iematol Educ Program, 2006:408-414.
5Linkins LA, Warkentin TE. The approach to heparin-induced thromboeytopenia. Semin Respir Crit Care Med, 2008, 29 : 66- 74.
6Warkentin TE, Sheppard JA, Sigouin CS, et al. Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia. Blood, 2006,108:2937-2941.
7Cruz-Gonzalez I, Sanchez-Ledesma M, Sanchez PL, et al. Heparin-indueed thrombocytopenia. Rev Esp Cardiol, 2007,60 : 1071-1082.
8Prechel M, Walenga JM. The laboratory diagnosis and clinical management of patients with heparin-induced thrombocytopenia: an update. Semin Thromb Hemost, 2008,34:86-96.
9Lewis BE, Wallis DE, Hursting MJ, et al. Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia. Chest, 2006, 129: 1407-1416.
10Greinacher A, Alban S, Omer-Adam MA, et al. Heparin-induced thrombocytopenia: a stoichiometry-based model to explain the differing immunogenicities of unfractionated heparin, low- molecular-weight heparin, and fondaparinux in different clinical settings. Thmmb Res, 2008,122:211-220.
